Trials / Recruiting
RecruitingNCT07105488
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 225 (estimated)
- Sponsor
- Bluefin Biomedicine, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BFB759 | BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis |
| DRUG | Placebo | Placebo for BFB759 |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2027-02-28
- Completion
- 2027-03-31
- First posted
- 2025-08-06
- Last updated
- 2026-04-06
Locations
35 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07105488. Inclusion in this directory is not an endorsement.